Concurrent Session 9:
Immunosuppressives

Chairs: Maroun Abou-Jaoude and Geoffrey McCaughan

Return to the Agenda:

NOTE: You can search this page by using your browser's "Find" function
(under the "Edit" menu in Netscape Navigator/Communicator and Microsoft Internet Explorer)

4:30 #99 Daclizumab induction immediately post liver transplantation to spare calcineurin inhibitors.

TG Heffron, GA Smallwood, AC Stieber and TG Boyer, Atlanta, GA

4:40 #100 Pharmacokinetic and pharmacodynamic evaluation of a two dose daclizumab regimen in liver transplantation. International Young Investigator Award

M Koch, G Niemeyer and B Nashan, Hannover, Germany

4:50 #101 The safety and efficacy of a two-dose daclizumab (Zenapax) induction therapy in liver transplant patients.

DE Eckhoff, B McGuire, M Sellers, J Contreras, L Frenette, S Hudson, C Ingram and S Bynon, Birmingham, AL

5:00 #102 The use of tacrolimus (TAC) and anti-CD₂ antibody Lo-CD2a (BTI-322) in adult liver transplantation (LT): preliminary results of a prospective randomized study.

JP Lerut, PF Laterre, O Ciccarelli, F Roggen, B Fraipont, S Talpe, C Sempoux, P Gianello, JB Otte, J Hope, H Bazin and D Latinne, Brussels, Belgium and Boston, MA

5:10 #103 Conversion to neoral® provides effective rescue therapy for liver transplant patients intolerant of prograf®. An interim analysis of a prospective study.

S Emre and M Abouljoud, New York, NY;Detroit, MI and

5:20 #104 Conversion from tacrolimus to cyclosporine A following primary liver transplantation under tacrolimus.

D Cataldo, A Jain, IR Marino, S Gruttadauria, VL Scott and JJ Fung, Pittsburgh, PA

5:30 #105 A clinical pharmacokinetic study of tacrolimus and sirolimus combination immunosuppression.

K Mahalati, V McAlister, K Petikian, J Dominguez, ZH Gao and AS MacDonald, Halifax, NS, Canada

5:40 #106 Absorption profile of RAD in de novo liver transplant patients.

GA Levy, D Grant, N Guilbault, K Paradis, S Appel-Dingemanse and JM Kovarik, Basel, Switzerland

5:50 #107 Cyclosporine metabolite pharmacokinetics and tolerability in stable hepatic allograft recipients comparing sangcya^TM oral solutions.

S-H Pan and R Lopez, Los Angeles, CA

Back to Top

Return to the Agenda